The world has witnessed a steady rise in both non-infectious and infectious chronic
diseases, prompting a cross-disciplinary approach to understand and treating disease …

In recent years, the rapid development of next-generation sequencing (NGS) technologies
has led to a significant reduction in sequencing cost with improved accuracy. In the area of …

The use of liquid biopsies for cancer detection and management is rapidly gaining
prominence. Current methods for the detection of circulating tumour DNA involve …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Though clinical trials for medical applications of dimethyl sulfoxide (DMSO) reported toxicity
in the 1960s, later, the FDA classified DMSO in the safest solvent category. DMSO became …

Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that
originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as …

Hypermethylation of the promoters of tumour suppressor genes represses transcription of
these genes, conferring growth advantages to cancer cells. How these changes arise is …

DNA methylation plays a critical role during development, particularly in repressing
retrotransposons. The mammalian methylation landscape is dependent on the combined …

Sequencing technologies have placed a wide range of genomic analyses within the
capabilities of many laboratories. However, sequencing costs often set limits to the amount …

DNA methylation is an epigenetic modification that plays an important role in regulating
gene expression and therefore a broad range of biological processes and diseases. DNA …